Emcure Pharmaceuticals Q2: Lenacapavir, EU GMP boost

Key developments Emcure flagged in Q2

Emcure Pharmaceuticals said the second quarter included multiple business updates spanning HIV, biologics, biosimilars, and India branded generics. Management also indicated a stronger push in dermatology, backed by building what it described as a top-class team for the Derma business. The company reiterated that in-licensing remains a core lever for portfolio expansion, alongside in-house development. Emcure positioned these moves around its stated focus on domestic and emerging markets.

Lenacapavir in-licensed from Gilead for India, emerging markets

A central update was Emcure’s in-licensing of Lenacapavir from Gilead Life Sciences for India and emerging markets. The company described Lenacapavir as a major development for the quarter and as a “path-breaking” product within antiretroviral (ARV) treatment regimes. Emcure said the deal strengthens its ARV portfolio and aligns with its focus on innovation and new product introductions. The company also underlined its existing strength in HIV, noting it is a major supplier to Sub-Saharan Africa and other regions.

Strategy: in-licensing and alliances remain in focus

Management said its approach of building alliances with multinational partners will continue, citing Sanofi as an example of prior collaboration. It added that in-licensing is “a major part of the job,” and that it will keep scanning for opportunities to build its domestic business. Separately, Emcure’s CEO referenced a Novo Nordisk partnership that, according to the company, positions it for an early entry into the obesity segment. Across these themes, Emcure’s stated intent is to augment its portfolio in focus markets through both in-licensing and internal development.

EU GMP approval for biologics facility and why it matters

Emcure said it recently received EU GMP approval for its biologics facility. Management linked the accreditation to faster approvals in targeted emerging markets, consistent with the company’s stated priority on domestic and emerging markets. It also indicated that the EU GMP tag could help accelerate processes in multiple countries where regulatory pathways recognise such inspections and standards. The company described this as a “reasonably good development” that could support filings and approvals going forward.

India business growth and the base business trend

In India, Emcure said it grew domestic business by 15% in the quarter, excluding Ferric Carboxymaltose. Management also said that without factoring Sanofi, its base business grew 7% to 8%, which it described as broadly in line with the industry. The company framed India as a priority market, and separately highlighted plans to improve reach and penetration, including in tier 2 and tier 3 markets.

Emerging markets and biosimilars: where traction is building

Management commentary suggested biosimilar traction is stronger in emerging markets where products qualify as biosimilars for their original approved indications. It said a larger runway could come once approvals are secured for an ischemic stroke indication, and that EU GMP accreditation could help fast-track that process across many countries. This sits alongside Emcure’s wider technology-driven focus that also includes complex injectables and biologics.

Manufacturing network: how capacity utilisation is shaping up

Emcure executives outlined utilisation trends across four plants. At the oral solids facility in Kadu, capacity utilisation has improved, with the plant also being used for ARV supplies including under PEPFAR. At the emerging markets plant in Mehsana, the injectable facility was described as having low utilisation and still in the filing phase, while the oral solids facility there is closer to 50% utilisation due to site transfers for Europe and Canada. The biosimilars facility, having received EU accreditation, is expected to be used for validation batches and product filings. Management also said the oncology block at Sanand is seeing momentum with increased capacity utilisation.

Europe supply ramp: DCP approvals and expected timeline

The company said it has started actively supplying in Europe after receiving approval under the DCP route. It added that each country typically takes three to five months for national approval following DCP, and that it expects these to start coming through from the end of the quarter. Based on that timeline, management expects the ramp-up in the second half of the year to be higher than in the first half.

Biotech platform: CHO products, mRNA ambition via Gennova

On the biotech side, Emcure said it has a CHO platform with five launched products and additional pipeline work. It also referenced capability in E. coli platforms, and highlighted interest in mRNA as a platform that could be used for vaccines in the future. Gennova Biopharmaceuticals, described as an Emcure subsidiary, has been identified in the provided material as developing an indigenous mRNA-based Covid-19 vaccine and as having launched biosimilar products. Separately, Emcure has said it has products across generics and biosimilars and continues to invest in R&D and manufacturing capabilities.

Snapshot table: what Emcure disclosed

Market impact and why investors track these milestones

For investors, the Lenacapavir in-licensing is material because it signals Emcure’s continued focus on differentiated products within HIV and ARVs, a segment where it already claims a strong presence. The EU GMP approval for biologics is important because it is directly linked by management to accelerating approvals in emerging markets, which can affect the pace of new launches and scale-up. Domestic growth commentary provides a reference point for how Emcure’s core India business is performing relative to the broader industry. The international business sales number of ₹1,238 crore and 15.8% YoY growth offers an additional anchor on overseas momentum during the quarter.

Conclusion

Emcure’s Q2 commentary centred on strengthening its product portfolio through in-licensing, expanding biologics readiness after EU GMP approval, and sustaining growth in India while building execution capacity across plants. The company also indicated a clearer second-half ramp in Europe as DCP-linked national approvals start to come through over three to five months. Management said it will continue to pursue multinational alliances, invest in R&D, and drive additional launches across focus therapeutic areas, including dermatology and biotech-led platforms.